Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib mesylate plus radiotherapy for advanced hepatocellular carcinoma
ChiCTR1800016448Phase 4Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Time to progression. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800016448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016448.